Pancreatic Cancer

Michel Ducreux, ESMO 2019 – Treating advanced pancreatic cancer

Published Online: October 3rd 2019

We joined Michel Ducreux at ESMO 2019 to discuss the challenges and recent advances in treating pancreatic cancer.

Questions
1. What are the major challenges in the treatment of advanced pancreatic cancer? (00:04)
2. Why is it important to treat advanced pancreatic cancer faster? (00:30)
3. What have been the most important recent clinical advances in the treatment of advanced pancreatic cancer? (01:06)
4. What advances have been made in the development of biomarkers to inform treatment decisions? (01:56)
5. How important is genetic testing to personalise therapy in pancreatic cancer? (02:39)

Michel Ducreux has participated in advisory boards for Roche, Merck Serono, Amgen, Novartis, Sanofi, Bayer, Lilly, Servier, Ipsen, MSD. He has acted as a symposium speaker for Roche, Merck Serono, Novartis, Ipsen, Lilly, Amgen and Bayer. He has received research funding from Roche, Merck Serono and Keocyt; and has an immediate family member who has other relationships with Sandoz.

Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.

touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.

Share this Video
Related Videos In Pancreatic Cancer
Pancreatic Cancer
Marcus S Noel
Developed by Touch
Marcus S Noel, ASCO GI22: Latest Advances in Pancreatic Cancer Treatment
Watch Time: 4 mins

touchONCOLOGY were thrilled to speak to Professor Marcus S Noel (Medstar Georgetown University Hospital, Washington, DC, USA) to summarise the latest developments and data from the ASCO Gastrointestinal Cancers Symposium 2022. Questions       What is the rationale for the use of L-asparaginase in the treatment of pancreatic cancer? 00:22-01:00       Could […]

Pancreatic Cancer
Developed by Touch
Benjamin A Weinberg, ASCO GI22: Pivotal Studies in Pancreatic Cancer
Watch Time: 8 mins

touchONCOLOGY were thrilled to speak to Professor Benjamin A Weinberg (Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA) to discuss the data from the TRYbeCA-1, KRYSTAL-1 and CISPD3 trials, which were presented at the ASCO Gastrointestinal Cancers Symposium 2022. Questions What are the hopes of the new drug delivery mechanism using L-asparaginase to treat […]

Pancreatic Cancer
Michel Ducreux, ESMO 2019 – Treating advanced pancreatic cancer

We joined Michel Ducreux at ESMO 2019 to discuss the challenges and recent advances in treating pancreatic cancer. Questions 1. What are the major challenges in the treatment of advanced pancreatic cancer? (00:04) 2. Why is it important to treat advanced pancreatic cancer faster? (00:30) 3. What have been the most important recent clinical advances […]

Trending In Pancreatic Cancer:

Marcus S Noel, ASCO GI22: Latest Advances in Pancreatic Cancer Treatment
Pancreatic Cancer
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72